The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Pharma Looks To Improve Potential Psychedelic Stroke Drug

  ()
Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September.
Tags:  Biotechnology / Pharmaceuticals

Three Analysts Like Healthcare Co.'s Upside

  ()
It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care.
Tags:  Biotechnology / Pharmaceuticals

New Drug Is Shown to Help Stopped or Reduced Bile Flow

Research Report
  ()
Albireo Pharma Inc.'s positive Phase 3 trial results indicate the medication would afford patients clinical and quality of life benefits, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

New DMD Drug Yields 'Compelling' Data

Research Report
  ()
A statistical reanalysis of trial results from Sarepta Therapeutics Inc. shows improved patient function, noted an Oppenheimer report.
Tags:  Biotechnology / Pharmaceuticals

Amended Agreement to Benefit Two Biotech Firms

Research Report
  ()
In the new arrangement between Beam Therapeutics Inc. and Verve Therapeutics Inc. each of the companies grants the other an exclusive license, one to a base editing target, the other to a gene delivery technology, noted a Wedbush report.
Tags:  Biotechnology / Pharmaceuticals

Co. Makes Financing Deals Around Two of Its Approved Drugs

Research Report
  ()
The agreements include milestone payments based on future revenue from sales of the biopharma Blueprint Medicines Corp.'s therapies, noted a Wedbush report.
Tags:  Biotechnology / Pharmaceuticals

Strong Data Suggest FDA Will Approve New Lymphoma Drug

Research Report
  ()
A green light is expected for the treatment after its developers submit a biologics license application for it, planned for H2/22, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

The FDA Is Expected to Approve New Narcolepsy Drug

Research Report
  ()
Avadel Pharmaceuticals Plc., the biopharma company behind this treatment, is currently undervalued and rated Outperform, noted an Oppenheimer report.
Tags:  Biotechnology / Pharmaceuticals

Trial of New Alzheimer's Drug Slated for Early 2023

Research Report
  ()
The biotech behind this product candidate differentiates itself from competitors with its approach to developing selective antibody therapies, noted an Argus Research Co. report.
Tags:  Biotechnology / Pharmaceuticals

Chen's Top Picks for Q3

  ()
Need to know where to go in these turbulent times? Asset manager Chen Lin has some ideas with his top picks for the third quarter.
Tags:  Biotechnology / PharmaceuticalsSilverOil & Gas - Exploration & Production

New Alzheimer's Drug Shows Promise as Monotherapy

Research Report
  ()
Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report.
Tags:  Biotechnology / Pharmaceuticals

Approval Likely of New Gel for Skin Condition, Analyst Says

Research Report
  ()
The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

New Positive Data Seem to Support Drug Label Expansion

Research Report
  ()
Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.
Tags:  Biotechnology / Pharmaceuticals

Results of Dermatitis Clinical Trial Due This Summer

Research Report
  ()
Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

New Drug for Heart Failure on Path to Approval, Analyst Says

Research Report
  ()
The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30

Research Report
  ()
The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Biotech Co. Advances 3 New Clinical Stage Assets

Research Report
  ()
Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report.
Tags:  Biotechnology / Pharmaceuticals

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise

Research Report
  ()
Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.
Tags:  Biotechnology / Pharmaceuticals

Showing Results: 26 to 50 of 116 Prev Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We are at a great entry point here for OMM here." ❭
– Clive Maund, CliveMaund.com
"LIO continues to build incredibly high-grade ounces of gold at depth." ❭
– Jay Taylor, Gold, Energy & Tech Stocks
"GRG is awaiting results from a drill program completed at Libanesa." ❭
– Siddharth Rajeev, Fundamental Research Corp.
"DV shareholders can expect ample news flow in H2/22 and into 2023." ❭
– Rick Mills, Ahead of the Herd
"OCG reported the thickest intercept from Santa Barbara so far." ❭
– Stuart McDougall, Research Capital Corporation